MedTech Capital: The Future of Funding - HYBRID

Virtual session

June 17, 2021 | 6:00 pm - 7:00 pm
Room: Delaware River Zoom

(Link will go live on 06/17/2021)

Please note this is a Hybrid event, meaning you can join in person or join via Zoom using the button above.

Join us for a panel discussion focused on the state of capital in the MedTech industry and the challenges to bringing innovative technologies to market. Learn about what opportunities are available, what VC’s are looking for, and what future trends may look like.

Introduction: Jed Cohen, Managing Director, Medical Supplies and Devices, SVB Leerink

Moderator: Tiffany Wilson, CEO, University City Science Center


  • Mary Amor, Head Ventures & Business Development, Siemens Healthineers
  • Chris Lloyd, Managing Director, Healthcare and Life Sciences, JP Morgan
  • Matt Plevelich, Principal, NewSpring Healthcare

Jed Cohen is a Managing Director in SVB Leerink’s investment banking practice, focused exclusively on the medical technology industry.  Jed joined Leerink in June 2009 and has approximately 27 years of health care investment banking experience, including 12 years at Citigroup.  Jed's transaction experience includes advisory work and financing assignments focused disproportionately on breakthrough medical device companies that are looking to create new markets or disrupt existing markets.  Jed received his Bachelor of Science in Economics from the University of Pennsylvania's Wharton School.

Tiffany Wilson brings more than 18 years of leadership transitioning innovative medical technologies from benchtop to bedside, building partnerships across academia, industry and economic development organizations.

She most recently served as CEO of Global Center for Medical Innovation (GCMI), an Atlanta-based non-profit dedicated to supporting the development and commercialization of innovative medical products. She joined GCMI in 2011 to lead its startup phase, establishing an overall vision, building strategic relationships and bringing together key stakeholders of the medical device ecosystem. Wilson’s strong background in medical devices, commitment to fostering innovation and understanding of business strategies propelled her into a leadership role in the Southeast and brought her into the national spotlight. Wilson served on the National Advisory Council on Innovation and Entrepreneurship (NACIE) of the U.S. Department of Commerce. She was recognized by Inc. Magazine as one of “17 Inspiring Women to Watch in 2017” and one of Becker Hospital Review’s “110 Women in Medtech to Know in 2017.”

Wilson earned a BBA in International Business from Loyola University and an MBA from Georgetown University McDonough School of Business. Wilson joined GCMI from Scientific Intake, where she served as the Vice President of Business Development and Strategy, evaluating marketing and distribution opportunities and driving product development projects for the global obesity market. Prior to Scientific Intake, she was Vice President of Corporate Strategy and Finance at ACell, Inc., a regenerative medicine and tissue engineering company based in Columbia, Maryland. At ACell, she led a broad range of initiatives including corporate finance, investor relations, strategic and operational planning, business development, regulatory, and reimbursement.

Wilson serves as Past President of the Board of the Southeast Medical Device Association (SEMDA), Founding Member of Medtech Women @ SEMDA, Chair of the Advisory Board for GCMI’s preclinical testing facility, and as a member of the Georgia Bio Board of Directors. She led the Sponsorship Committee of the 2013 SEMDA Conference and has served as the Co-Chair of the Medical Device Subcommittee of the Metro Atlanta Chamber Bioscience Leadership Council. In 2015 Wilson received the prestigious Georgia Bio Community Award and in 2017 she was presented with the Industry Growth Award, the highest honor bestowed each year by Georgia Bio.

Mary Amor

Chris Lloyd is a Managing Director of J.P. Morgan’s Healthcare and Life Sciences business for the Northeast where he leads a dedicated team serving the needs of high growth companies in the biotech, healthcare IT, medical device and healthcare services markets. He previously ran Comerica Bank’s Technology & Life Sciences group on the east coast, working with venture capital and private-equity backed technology and healthcare businesses. Chris graduated with a degree in finance from Brigham Young University and received an MBA from Columbia Business School.

Matt Plevelich: is a Principal at NewSpring with the Firm’s dedicated healthcare strategy, NewSpring Healthcare. Matt joined NewSpring in 2008 and has over 10 years of experience focused on the sourcing, underwriting and execution of new investments as well as the monitoring of existing investments. While completing his degree, Matt spent considerable time as an intern in the Office of the Vice Chairman at Washington D.C.'s largest full-service investment bank, Ferris Baker Watts, where he performed in-depth research for high-net-worth clients. He also spent a summer as an intern at NewSpring. Current NSH boards include: BRC Healthcare, Verisma (observer), ContinuumRx (observer), SUN Behavioral Health (observer), Mangrove Management Partners (observer). He received a BBA with a concentration in Finance from The George Washington University.

June 17, 2021
Venture Café Philadelphia is powered by Science Center.